Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FGFR2::v status confers therapeutic sensitivity to Elacestrant in patients with Intrahepatic Cholangiocarcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.